Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas.

Trial Profile

A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Uprosertib (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors GlaxoSmithKline; GSK
  • Most Recent Events

    • 03 Apr 2018 Results assessing safety, tolerability, pharmacokinetics and pharmacodynamic published in the Investigational New Drugs
    • 07 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 May 2013 Planned end date changed from 1 Sep 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top